Search clinical trials for: rivaroxaban

Total 474 results

Ottawa Hospital Research Institute
University of Alberta; Hamilton Health Sciences Corporation; Queen Elizabeth...

Completed

Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines (TRIM-Line)

Cancer | Central Venous Catheter Thrombosis | Upper Extremity Deep Vein Thrombosis

Canada
Bayer
Janssen Research & Development, LLC

Not yet recruiting

An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure

Children | Congenital Heart Disease | Prevention of Venous Thromboembolism | Fontan Procedure

Japan
Huashan Hospital
Peking Union Medical College Hospital; West China Hospital

Recruiting

Postoperative Thrombosis Prevention in Patients With CD

Pulmonary Embolism | Cushing Disease | DVT

China
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China (XAPEC)

Pulmonary Embolism

China
University of Karachi
Center for Bioequivalence Studies and Clinical Research (CBSCR), HEJ Research... and other collaborators

Completed

Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed Conditions (Bioequivalence)

Bioequivalence

Pakistan
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan

Non-valvular Atrial Fibrillation (NVAF)

Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study (X-PRESS)

Atrial Fibrillation

Taiwan
Bayer

Withdrawn

Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement) (XYRIS)

Total Hip Replacement | Total Knee Replacement | Prophylaxis, Thromboembolism, Venous
The Young Investigator Group of Cardiovascular...

Completed

Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT)

Left Ventricular Thrombosis | Anticoagulants; Increased

Egypt
Bayer
Janssen Scientific Affairs, LLC

Completed

Use of Direct Oral Anticoagulants in UK

Stroke

United Kingdom
Kevin H.M. Kuo, MD, MSc, FRCPC

Recruiting

THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) (THIS)

Sickle Cell Disease | Venous Thromboembolism | Central Venous Catheter Thrombosis

Canada
Bayer
Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical...

Recruiting

An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism

Venous Thromboembolism

Japan
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (RECORD 2)

Venous Thromboembolism | Prevention

Denmark, Italy, China, Indonesia, Colombia, Portugal, United States, Australia, Korea, Republic of, Taiwan, Canada, Estonia, New Zealand, Brazil, Mexico, South Africa, Peru, United Kingdom, Latvia, India, Lithuania, Sweden, Norway
Bayer
Janssen Research & Development, LLC

Completed

Dose-confirmatory Bridging Study in Total Hip Replacement

Venous Thromboembolism

Japan
Bayer
Janssen Scientific Affairs, LLC

Completed

Dose-confirmatory Bridging Study in Total Knee Replacement

Venous Thromboembolism

Japan
Bayer

Completed

Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

Venous Thromboembolism

Italy, Spain, Poland, United States, Czech Republic, Canada, Denmark, Netherlands, Belgium, Chile, Slovakia, Hungary, Austria, France, Germany, South Africa, Sweden, Turkey, Colombia, Israel, Mexico, Argentina, Norway, Brazil, Lithuania, ... and more
Shanghai Ninth People's Hospital Affiliated to...
Boston Scientific Corporation

Enrolling by invitation

Preservation of Venous Valvular Function After PMT for Acute DVT (PREFER)

Acute Deep Venous Thrombosis of Femoral Vein (Disorder)

China
Insel Gruppe AG, University Hospital Bern
Bayer; Janssen Pharmaceuticals

Completed

Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery (BARIVA)

Bariatric Surgery

Switzerland
University Hospital, Brest
Bayer

Completed

Pharmacokinetics of Rivaroxaban After Bariatric Surgery (ABSORB)

Morbid Obesity | Bariatric Surgery

France
Bayer
Janssen Research & Development, LLC

Completed

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes (RIVA-DM)

Atrial Fibrillation

United States
Bayer
Janssen, LP

Completed

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) (REATTAIN)

Atrial Fibrillation

Sweden
Bayer
Janssen Research & Development, LLC

Completed

Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet

Biological Availability

Germany
Brazilian Clinical Research Institute
Alliança Diagnostic

Not yet recruiting

Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke (ARCHIMEDES)

Ischemic Stroke
Foundation University Islamabad
Shaheed Zulfiqar Ali Bhutto Medical University

Unknown

Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis (CVT)

Cerebral Venous Thrombosis
Bayer

Completed

Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

Venous Thromboembolism

Germany
Bayer
Janssen Research & Development, LLC

Completed

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEIN Jr)

Venous Thromboembolism

Belgium, China, Hong Kong, United States, Switzerland, Spain, Russian Federation, Singapore, Canada, Germany, Netherlands, United Kingdom, Austria, Brazil, Israel, Italy, Mexico, Turkey, France, Australia, Finland, Hungary, Japan, Arg... and more
Hanoi Medical University
Bach Mai Hospital

Unknown

Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching

Thrombosis | Deep Vein Thrombosis | Surgery--Complications

Vietnam
Diagnostica Stago

Completed

Validation of Rivaroxaban Assay for US Registration

Patients Receiving Rivaroxaban Treatment

United States
Bayer

Completed

Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (ODIXa-HIP2)

Venous Thromboembolism

Italy, Spain, Denmark, Netherlands, Belgium, Austria, Germany, Poland, Sweden, Israel, France, Norway, United Kingdom
Pfizer

Completed

Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf) (SPAF)

Atrial Fibrillation

Spain
PharmEvo Pvt Ltd

Withdrawn

Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin

Atrial Fibrillation | Mitral Valve Stenosis

Pakistan
Bayer
Janssen Research & Development, LLC

Completed

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA)

Venous Thrombosis | Deep Vein Thrombosis

Switzerland, France, Germany, Hungary, Spain, Sweden, Austria, Czech Republic, Italy, Moldova, Republic of, Slovenia, Ukraine, United Kingdom, Israel, Portugal, Belgium, Denmark, Greece, Netherlands, Canada, Norway
Bayer

Completed

Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement (ODIXaHIP-OD)

Venous Thromboembolism

Italy, Spain, Denmark, Netherlands, Belgium, Austria, Germany, Poland, Sweden, Israel, Norway, United Kingdom, France
Centre of Postgraduate Medical Education

Unknown

Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.

Blood Loss | Hip Osteoarthritis

Poland
University of Sao Paulo General Hospital

Recruiting

Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery (TASK-POAF)

Atrial Fibrillation New Onset

Brazil
University Hospital, Angers
Bayer

Recruiting

AntiCoagulants and COGnition (ACCOG)

Nonvalvular Atrial Fibrillation

France
Bayer
Janssen Research & Development, LLC

Completed

A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)

Treatment of Venous Thromboembolism in Cancer Patients

United Kingdom
Janssen Research & Development, LLC
Bayer

Completed

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

End-Stage Renal Disease

United States
Insel Gruppe AG, University Hospital Bern

Completed

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial (ELAN)

Ischaemic Stroke

Belgium, Ireland, Israel, Germany, India, United Kingdom, Austria, Switzerland, Finland, Norway, Italy, Portugal, Slovakia, Japan, Greece
Bayer
Janssen Research & Development, LLC

Not yet recruiting

A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE) (XAPAEDUS)

Venous Thromboembolism | Children Under 2 Years

Spain, Sweden, Denmark, France
Susan Smyth
Janssen Scientific Affairs, LLC

Terminated

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis (XENITH)

Venous Thrombosis | Pulmonary Embolism
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon (ReLoaDeD)

Atrial Fibrillation

Germany
Boehringer Ingelheim
Health ResearchTx, LLC (HRTX); inVentiv Health Clinical (iVH); United States...

Completed

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty (XAMOS)

Venous Thromboembolism

Switzerland, China, Slovakia, France, Germany, Hungary, Korea, Republic of, Singapore, South Africa, Spain, Sweden, Philippines, Australia, Austria, Colombia, Czech Republic, Estonia, Hong Kong, Italy, Latvia, Lebanon, Lithuania, Macedonia... and more
Bristol-Myers Squibb

Completed

Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients

Atrial Fibrillation
Bristol-Myers Squibb

Completed

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

Atrial Fibrillation
Henan Institute of Cardiovascular Epidemiology

Completed

Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty

Acute Coronary Syndrome

China
Bayer
Janssen Research & Development, LLC

Completed

Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA LEA)

Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)

Turkey, Russian Federation, Korea, Republic of, Mexico, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Egypt, Kazakhstan, Algeria, Lebanon, Saudi Arabia, Ukraine, Jordan, Kenya, Kuwait, Morocco, Qatar, United Arab Emirates
David Anderson
Canadian Institutes of Health Research (CIHR)

Completed

Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II)

Venous Thromboembolism

Canada
Johnson & Johnson Pharmaceutical Research & Development...
Bayer

Completed

Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)

Acute Coronary Syndrome

Search clinical trials for: rivaroxaban

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations